

Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems

Mark S. Gold⁸, Kenneth Blum,^{1-7,10} Marcelo Febo¹, David Baron,² Edward J Modestino⁹, Igor Elman¹⁰, Rajendra D. Badgaiyan¹⁰

¹Department of Psychiatry, McKnight Brain Institute, University of Florida, College of Medicine, Gainesville, FL, USA, ²Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, ³Global Integrated Services Unit University of Vermont Center for Clinical and Translational Science, College of Medicine, Burlington, VT, USA, ⁴Department of Addiction Research, Dominion Diagnostics, LLC, North Kingstown, RI, USA, ⁵Center for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purbe Medinpur, West Bengal, India, ⁶Division of Neuroscience Research and Therapy, The Shores Treatment and Recovery Center, Port St. Lucie, FL, USA, ⁷Division of Nutrigenomics, Sanus Biotech, Austin TX, USA, ⁸Department of Psychiatry, Washington University School of Medicine, St. Louis, Mo, USA, ⁹Department of Psychology, Curry College, Milton, MA USA,, ¹⁰Department of Psychiatry, Wright State University, Boonshoft School of Medicine, Dayton, OH, USA.

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Anhedonia and food addiction
4. Anhedonia in RDS Behaviors
5. Anhedonia hypothesis and DA as a “Pleasure” molecule
6. Reward genes and anhedonia: potential therapeutic targets
7. Anti-reward system
8. State of At of Anhedonia
9. Conclusion
10. Acknowledgement
11. References

1. ABSTRACT

Anhedonia is a condition that leads to the loss of feelings pleasure in response to natural reinforcers like food, sex, exercise, and social activities. This disorder occurs in addiction, and an array of related neuropsychiatric syndromes, including schizophrenia, depression, and Post Traumatic Stress Disorder (PTSD). Anhedonia may be due to derangements in mesolimbic dopaminergic pathways and their terminal fields (e.g., striatum, amygdala, and prefrontal cortex) that persist long after the traces of the causative drugs are eliminated (pharmacokinetically). Here we postulate that anhedonia is not a distinct entity but is rather an epiphenomenon of hypodopaminergic states and traits arising from the interaction of genetic traits and epigenetic neurobiological alterations in response to environmental influences. Moreover, dopaminergic activity is rather complex, and so it may give rise to differential pathophysiological processes such as incentive sensitization, aberrant learning and stress-

like “anti-reward” phenomena. These processes may have additive, synergistic or antagonistic interactions with the concurrent reward deficiency states leading in some instances to more severe and long-lasting symptoms. Operant understanding of the neurogenetic antecedents to reward deficiency syndrome (RDS) and the elucidation of reward gene polymorphisms may provide a map for accessing an individual’s genetic risk for developing Anhedonia. Prevention techniques that can restore homeostatic balance via physiological activation of dopaminergic receptors (D2/D3) may be instrumental for targeting not only anhedonia per se but also drug craving and relapse.

2. INTRODUCTION

Anhedonia is a condition that leads to loss of the ability to experience pleasure in response to

natural reinforcers like food, sex, and exercise, and social activities. Newer models consider motivational anhedonia; lack of motivation and activity without pleasure and consummatory anhedonia (1). Meanwhile, the debate regarding the neurobiological basis of anhedonia remains unsettled. There is, however, a broad consensus regarding the involvement of the mesolimbic dopaminergic reward pathways. These pathways do not exist in isolation but rather are found embedded within a complex network of interrelated systems; opioidergic, noradrenergic and serotonergic, to name a few, each of which exhibits a unique function within the context of pleasure-related behavior.

Anhedonia, accompanied by hyporesponsive reward circuits (2), is an important characteristic of neuropsychiatric syndromes including mood disorders, schizophrenia, and all Reward Deficiency Syndrome (RDS) behaviors including substance use disorders, post-traumatic stress disorder (PTSD), borderline personality disorder, and schizoid personality disorder (3). Keedwell & Linden (4) found that the brains of participants who were clinically depressed had to work harder to process rewarding experiences. Anhedonia is also a side effect of antidopaminergic neuroleptics or antipsychotic drugs which block dopamine (DA) binding to postsynaptic neuronal loci (5, 6). One reason for the high prevalence of nicotine addiction in people with psychiatric illness, especially those on psychiatric medications (7) is that smoking is used as self-medication to counter boredom in an attempt to reverse antipsychotic-related anhedonia (8). The clinically anhedonia has profound implication since it as a risk factor for suicide particularly in patients with substance use disorders (SUD)s (9).

Increases in dopamine levels in mesolimbic dopaminergic pathways including their terminal fields; the striatum, amygdala, and prefrontal cortex, are the sites where the rewarding effects of natural rewards, as well as, drugs of abuse underlying the subjective pleasure or “high” pursued by drug addicts occur. However, the precise nature of dopaminergic action is a subject of complementary/competing hypotheses encompassing reward anticipation, learning, and motivation (10-13). Work by Schultz and associates in monkeys demonstrated several thousand-fold variabilities in the speed of phasic DA release and offered a means to understand the relationship between DA and anhedonia. They found that DA mediates the (epigenetic) reactivity of the organism to the environment at different time scales. In simple terms, environmental cues will change the quantal neuronal release of dopamine from either fast impulse reward related to much slower and lower quanta release when the environmental cue is uncertain (13). These environmental cues will impact postsynaptic dopamine tone even when dopamine function is

deficient as observed in Parkinson’s disease and RDS behaviors (9).

3. ANHEDONIA AND FOOD ADDICTION

While it is important to continually perform both animal and human research conceptualizing the commonality of food and drug addiction, it is clear that highly reinforcing drugs of abuse reduce interest in eating while withdrawal of some of these drugs increase eating (14). In clinical settings “never get too hungry” is an anti-drug relapse mantra (15). Anhedonia during withdrawal states or due to other causes appears to result from the neurochemical effects of both substances such as glucose and opioids. Neuroimaging data, related to reward circuit responsivity and weight gain, adequately address this concept in humans (16, 17). Work by Ahmed (18), in the Oxford publication “Food and Addiction” proposes that in nonhungry, nonthirsty rats, the taste sensation associated with ingestion of sweetened water is clearly more rewarding than artificial sensations from intravenous cocaine, independent of prior cocaine history. Moreover, this conclusion was generalized to intravenous heroin; however, heroin was more potent than cocaine in competing with a sweet taste, especially with chronic heroin use (19).

Along these lines, Johnson *et al.* (20) proposed that Attention Deficit Hyperactivity Disorder (ADHD) may associate with disrupted dopamine signaling whereby dopamine D2 receptor numbers are decreased in reward-related brain regions. They correctly point out that the same pattern exists in various RDS behaviors; drug or food (sugar) addiction and obesity. In simple terms, these authors hypothesize that chronic sugar intake could lead to reduced mesolimbic dopamine signaling or a hypodopaminergic state that contributes to ADHD symptomatology. This mesolimbic reduced signaling may have real relevance in low dopamine tone in ADHD as measured by Badgaiyan *et al.* (21) raising the question of “the Chicken or Egg.” The DRD2 A1 allele, with a well-known 30-40% lower D2 receptor density than the normal A2, has a genetic association with ADHD. This DRD2 A1 deficit would suggest an additive insult; a co-morbid enhanced craving for sugar or other neuronal releasers of dopamine at the nucleus accumbens (NAc). reward site. Also, Badgaiyan *et al.* (21) found that in ADHD the phasic dopamine response to stimuli is heightened thereby providing continued impetus to seek out sugar and possibly anhedonia (“sugar blues”).

4. ANHEDONIA IN RDS BEHAVIORS

Reward Deficiency Syndrome, first coined by Blum *et al.* in 1996, (22) has received considerable attention and represents a conceptual framework for understanding the role of, for example, dopaminergic

genetics and epigenetics in not only drug and alcohol abuse, but all addictive, impulsive and compulsive behaviors. There are many clinical subtypes, and even schizophrenia has been included in this list (22).

Addictive drugs enhance the functioning of the reward circuitry after they are self-administered by laboratory animals. The core reward circuitry is an 'in-series' circuit that links the ventral tegmental area (VTA), the nucleus accumbens (NAc) and the ventral pallidum via the medial forebrain bundle. As mentioned earlier, although originally believed to encode a set point for hedonic tone, these circuits are now, thought to be far more complex, being involved in the mediation of encoding for attention, reward expectancy, disconfirmation of reward expectancy, and incentive motivation. Moreover, 'hedonic dysregulation' or anhedonia, of these circuits might facilitate addiction.

The crucial addictive-drug-sensitivity component is the 'second-stage' dopaminergic component in this reward circuitry (23). Addictive drugs have in common that they enhance dopaminergic reward synaptic function (directly or indirectly or even trans-synaptically) in the NAc. Nucleus accumbens DA levels regulate drug self-administration to maintain a desired hedonic level and keep NAc DA, within a specific, elevated range (22). Chronic use of some classes of addictive drugs like opiates results in the development tolerance to the euphoric effects. Post-use dysphoria then dominates the reward circuit hedonic tone, and people who are addicted use drugs to get back to normal ('get straight'). The brain circuits that mediate the pleasurable effects of addictive drugs are different anatomically, neurophysiologically and neurochemically from those mediating physical dependence, as well as, from those mediating craving NAc and relapse (pre-frontal cortex –cingulate gyrus and central amygdala). Gardner, (24), pointed out that drug addiction involves a progression from occasional (recreational) to impulsive and finally compulsive (habitual) use. The behaviors progress from reward-driven to habit-driven drug-seeking. Moreover, they correlate with neuroanatomical progress from the ventral striatum NAc to dorsal striatal control over drug-seeking behavior.

Variations in vulnerability to drug addiction are due to genetics, yet exposure as an adult or during childhood and *in utero*, to environmental factors such as stress, trauma, and social defeat also epigenetically alter brain reward mechanisms and symbiotically impart vulnerability to addiction. The etiology of substance abuse and even schizophrenia hold very well to the 'bio-psycho-social' model (25, 26). Human neuroimaging studies add credence to the hypothesis that addiction to cocaine (27) or other substances correlates with a hypodopaminergic dysfunctional state within the reward circuitry of

the brain as suggested by the RDS model (28). Serotonergic, opioid, endocannabinoid, GABAergic and glutamatergic mechanisms are implicated in addiction by credible evidence. For example, a recent study using magnetic resonance imaging points to a role for polymorphisms of catabolic enzymes like Catechol-O-Methyl –Transferase (COMT) in white matter integrity (29). Three standard triggers for craving and relapse are (a) re-exposure to the addictive drug, (b) stressors, and (c) reexposure to people, places, and objects (environmental cues) previously associated with drug-taking behavior. Drug-triggered relapse involves the NAc and the neurotransmitter DA. Relapse triggered by stress involves the central nucleus of the amygdala, the bed nucleus of the stria terminalis, corticotrophin-releasing factor, and the lateral tegmental noradrenergic nuclei of the brain stem and the neurotransmitter norepinephrine. Finally, relapse triggered by environmental cues involves the basolateral nucleus of the amygdala, the hippocampus, and the neurotransmitter glutamate. Knowledge of the neuroanatomy, neurophysiology, neurochemistry, neuropharmacology and neurogenetics of the activity of addictive drugs is producing some strategies for Pharmacogenomics and nutrigenomic treatment of RDS behaviors (30). In fact, one interesting natural substance L-acetyl-carnitine, a substance having acetylcholine-like pharmacological activity (31) has been shown to attenuate anhedonia associated with alcohol dependence (32).

5. ANHEDONIA HYPOTHESIS AND DOPAMINE CHARACTERIZED AS A "PLEASURE" MOLECULE

Before the RDS concept, the anhedonia hypothesis of neuroleptic action (33) was, from its inception, the DA hypotheses of reward (34) or reinforcement (35). Dackis & Gold placed significant value on the role of DA depletion in cocaine-seeking behavior and relapse (36). Moreover, the dopamine hypotheses were themselves deviations from an earlier noradrenergic theory of reward introduced by Larry Stein (37). The anhedonia hypothesis (38) was that brain dopamine plays a critical role in the subjective pleasure associated with positive rewards. According to Wise (39, 40), the hypothesis "was intended to draw the attention of psychiatrists to the growing evidence that dopamine plays a critical role in the objective reinforcement and incentive motivation associated with food and water, brain stimulation reward, and psychomotor stimulant and opiate reward" (39).

Neuroleptics are drugs used to treat schizophrenia a condition involving anhedonia. They act like D2 receptor inhibitors known to block the postsynaptic interaction of dopamine released into the synapse. Some studies revealed that neuroleptics attenuated the positive reinforcement that we normally

associate with pleasure in laboratory animals (41, 42). Psychiatrists, have correctly pointed out that the acute actions of neuroleptics, blocking postsynaptic dopamine interaction, were reflected in animal studies whereas in human schizophrenia neuroadaptations to chronic neuroleptic administration, appear to alleviate symptoms induced by elevated DA in schizophrenia, without effecting the symptoms of neuroleptic induced decreased DA including anhedonia and RDS (25, 43).

Wise (40) also points out that despite its limited heuristic value for the understanding of schizophrenia, the anhedonia hypothesis has sponsored biological theories of reinforcement, motivation, and the neuroepigenetics of addiction (44). Brain dopamine plays a major role in reinforcement of response habits, conditioned preferences, and synaptic plasticity in cellular models of learning and memory (45). The idea of the central role of DA in reinforcement is also the basis of the psychomotor stimulant theory and most neuroadaptation theories of addiction, and also to conditioned reinforcement and reward deficiency prediction. Properly understood, it is also fundamental to the theories of incentive motivation (46). It is known that distinct populations of D1- and D2-dopamine receptor expressing medium spiny neurons (D1-/D2-MSNs) comprise the NAc and stimulation of D1-MSNs promote activity, while activation of D2-MSNs inhibit motivated behavior. Heinsbroek and colleagues (47) most recently reported that either increasing activity in D1-MSNs or decreasing activity in D2-MSNs augmented cue-induced reinstatement. In fact, they also found using optogenetic implementation, that GABAergic long-term depression (LTD) was abolished in D2- but not in D1-MSN synapses of mice trained to self-administer cocaine. Moreover, in cocaine-trained mice a mu opioid receptor antagonist restored GABA currents in D2-, but not D1-MSN synapses, thus, increased enkephalin tone on presynaptic mu receptors was responsible for occluding the LTD. Accordingly, a behavioral function for D1-MSN innervation of the ventral pallidum identified by these results suggests that loss of LTDGABA in D2-MSN, but not D1-MSN input to ventral pallidum may promote cue-induced reinstatement of cocaine-seeking behavior (49).

The notion that DA might be necessary for pleasure itself came in part from the subjective reports of patients (48) and healthy volunteers (49, 50) given neuroleptic treatments. The dysphoria caused by neuroleptics is quite consistent with the concept that they attenuate the normal pleasures of life. Consistent with this view (51, 52) drugs like cocaine and amphetamine and even palatable food substances are presumed to be addictive because of the pleasure they impart (53) by increasing extracellular dopamine levels (54-56). Furthermore, although controversial, (57) the neuroleptic pimozide, a competitive antagonist at

dopamine receptors, has been reported to decrease euphoria induced by IV amphetamine in healthy volunteers (58, 59). The cannabinoids (THC) can increase sucrose palatability so that after pretreatment with THC sucrose, acquires the ability to induce DA release in the NAc shell and after repeated exposure to this hedonic taste, this property will undergo adaptation (habituation) (60).

Finally, Bressan and Crippa (61) reviewed preclinical data concerning the role of DA in reward and pleasure behaviors. They utilized a computer-based search of the literature, augmented by extensive bibliography guided article reviews to find basic information on dopamine and symptoms such as dysphoria, anhedonia, and depression. Their results indicated that central dopaminergic neurotransmission is complex, having multiple actions at each level of the mesocorticolimbic reward pathway. Moreover, DA has a role in reward processing and indeed influences the ability to experience pleasure. The authors highlight that dysfunction of reward circuit DA transmission is related to symptoms including apathy anhedonia, and dysphoria found in several neuropsychiatric disorders. Disorders that involve DA dysfunction include; Parkinson's disease, depression, drug addiction, and neuroleptic-induced dysphoria. However, there are others (11, 62) who refute the idea that dopamine is indeed a "pleasure molecule" and question its role in orgasmic response during copulation.

6. REWARD GENES AND ANHEDONIA: POTENTIAL THERAPEUTIC TARGETS

Many reward based genes have distinctive effects regarding mood including anhedonia. A PubMed search of these reward genes and associated polymorphisms in psychiatric disorders or "Psychiatric Genetics" has resulted in over 18,000 papers. A selective sampling includes many important references having relevance to both hedonic and anhedonic responses (13, 63-110).

Regarding anhedonia per se, a brief search provides a few recent strong examples of how specific gene polymorphisms affect the mood and more specifically anhedonia. Understanding these gene-environment interactions may provide important insight for future therapies. There is mounting evidence that the NAc has a central role in the pathophysiology of anhedonia. The hypothesis has been that anhedonia, is a core symptom of depression, and might be related to dysfunction of the NAc brain region a fundamental component of the reward circuitry. Bessa *et al.* (111) have shown that medium spiny neurons in the NAc have hypertrophied in animals displaying anhedonic behavior. These animals have also shown increased expression of the genes that encode synaptic protein brain-derived synapsin 1, brain region neurotrophic

factor, and neural cell adhesion molecule (genes associated with dopaminergic regulation). The authors propose that stress induces anhedonic behavior is related to specific changes in the neuronal morphology and the gene-expression of the NAc.

Clinically, the gene expressions that caused by stress are, in effect, reversed after treatment with antidepressants. Furthermore, transcriptional profiling of the NAc for Rho GTPase-related genes, known regulators of synaptic structure, resulted in a sustained reduction in RAS-related C3 botulinum toxin substrate 1 (RAC1) expression after chronic social stress. Golden *et al.* (112) found that overexpression of constitutively active RAC1 in the NAc of mice after chronic social defeat stress; reverses anhedonia. Interestingly, TREK1 is another crucial gene expressed in reward-related basal ganglia regions. The TREK1 genetic variation may associate with anhedonic symptoms of depression as well as the Trace Amine-Associated Receptor 1 (TAAR-1) (113). Dillon *et al.* (114) found that the total number of “protective” TREK1 alleles was associated with stronger responses to monetary incentive gains in several other reward-related regions, including the dorsal anterior cingulate cortex, orbitofrontal cortex, and mesial prefrontal cortex. The authors conclude that future studies in depressed samples should evaluate whether variation in neural responses to rewards could contribute to the association between TREK1 and antidepressant response in humans.

Law *et al.* (115) found that in mood disorder, early stressors, such as parental separation, are vulnerability factors which provoke hippocampal gene expressions. They conclude that deprivation in the early life of a nonhuman primates, without subsequent stressors, has long-term effects the expression of genes implicated in synaptic function and plasticity within the hippocampus. The reductions in serotonin 1A and GAP-43 receptor expression are similar to findings in mood disorder and support the possibility that these reductions reflect an early developmental contribution to anhedonia vulnerability. It is well established that drugs of abuse alter expression of AMPA-type glutamate receptor subunits (GluRs) in the NAc. Todtenkopf and colleagues (116) found that elevated GluR1 in NAc shell increases intracranial self-stimulation (ICSS) thresholds, similar to the effects caused by treatments that cause anhedonia and dysphoria (pro-depressive effects) in rats and humans, for example, drug withdrawal, like kappa-opioid agonists. On the other hand, elevated GluR2 decreases ICSS thresholds, an effect like that caused by drug abuse reward.

Human neuroimaging studies have demonstrated that inflammatory cytokines target basal ganglia function and presynaptic DA, leading to

symptoms of anhedonia. Felger *et al.* (117) found that *in vivo* microdialysis demonstrated decreased release of DA after four weeks of Interferon (IFN)-alpha administration compared to saline. PET neuroimaging also showed decreased DA release after four weeks of IFN-alpha as evidenced by reduced displacement of the DA ligand 11C-raclopride following amphetamine administration. Additionally, four weeks of IFN-alpha associated with decreased D2R binding but no change in the DA transporter. Importantly, during IFN-alpha administration, sucrose consumption was attenuated and correlated with decreased DA release at four weeks as measured by *in vivo* microdialysis. From these results, the authors conclude that chronic peripheral IFN-alpha exposure reduces striatal DA release and occurs with anhedonia-like behavior in non-human primates.

Cocaine is often proposed as the extreme but an ideal model for all stimulant addiction can be self-administered, to the point of death, in animal studies. Withdrawal from psychostimulants, like cocaine or amphetamines, in animal models, are useful for screening antidepressants (118). In humans post cocaine or amphetamine addiction leads to a ‘burn out’ which looks very much like depression with psychomotor retardation. However, once that passes, individuals in recovery report hyperphagia and hypersexuality associated with anhedonia. This anhedonia is a major factor in craving and relapse. The DSM-V recognizes that social, occupational and recreational activities decrease and are replaced by repeated drug use while previously rewarding experiences like food, job, and family become devalued as dependent persons, despite serious negative consequences to seek and use the drug.

Findings by Carelli and West (119) reveal that cocaine-conditioned cues elicit a ‘cocaine-need state’ that is aversive, encoded by a distinct subset of NAc neurons, and rapid dopamine release that induces cocaine-seeking behavior. Other experiments (88) revealed that bidirectional control (inhibition or excitation) of specified midbrain dopamine neurons immediately and bi-directionally modulate (120) (induces or relieves) multiple independent depressive symptoms such as anhedonia caused by chronic stress. These authors also found that optogenetic recruitment of these dopamine neurons potentially alters neural encoding of anhedonia in downstream in the NAc of freely moving rodents. This work suggests that processes affecting anhedonia may involve alterations in the neural encoding of action in limbic circuitry (121). Accordingly, even high-fat diets attenuate dopamine signaling with an increase in anhedonia associated behaviors in rodents similar to drugs of abuse (122). The similarity further suggests that agonistic dopaminergic functioning may induce anti-anhedonia.

The role of chronic stress in rodents suggest an effect on dopamine D1 receptor excitation of melanocortin 4 receptor which is responsible in part of inducing anhedonia. Lim *et al.* (123) found that despite increases in behavioral measurements of anhedonia elicited by stress, measurements of behavioral despair are not increased; they are prevented by blocking these melanocortin 4 receptor (MC4R)-mediated synaptic changes *in vivo*. Further in an animal model with experimentally induced chronic social defeat stress (CSDS) reduced dopaminergic activity was observed (123). This work suggests that specific alteration of dopaminergic reward processes might be altered by CSDS induced anhedonia. Additionally, in the social defeat model of depression in rats, hypothalamic dynorphin and orexin were diminished, noteworthy because most hypothalamic orexin cells co-express dynorphin. Accordingly, these observations suggest that in anhedonia, orexin and dynorphin function may be out of balance between the mesocortical dopaminergic regions and the hypothalamus (124, 125).

7. ANTI-REWARD SYSTEM

The decrease in dopamine production is progressively worsened by the release of the k opioid receptors' agonist, dynorphin. This type of between-system anti-reward neuroadaptation is also characterized by the massive outpouring of stressogenic neurotransmitters like norepinephrine and corticotropin-releasing factor, which worsen anhedonia. Additionally, anhedonia needs to be examined in the context of the incentive motivation theory which considers the brain reward function as composed of core motivational and emotional processes termed "wanting" and "liking" respectively. Decreases in striatal dopamine concentrations underlying reward deficiency prompt sensitization in the key effector systems. Effector systems include pre- and post-synaptic dopamine receptors, presynaptic dopamine transporters, and the enzymes involved in dopamine's metabolism are all are responsible for transforming normal motivational "wanting" responses into the heightened salience engendered by drugs or drug-related cues. This sensitization is construed to be an animal homolog of human craving (126). "Aberrant learning theory" is a closely related concept which suggests that new rewards are predicted by interactions between tonic and phasic spikes in dopaminergic neurons phasic firing by the expectancy of the old rewards or encoding (learning) new rewards (57, 65). Hence, neural adaptations to hypodopaminergia of reward deficiency may not only lead to low signal-to-noise detection capability for natural rewards, but also to the motivational significance of cues that predict delivery of drugs, are overlearned meaning that drugs are constantly perceived to be better than expected (92, 127, 128).

Types of the interactions with reward deficiency are determined by; nature, the concurrent neuroadaptations, and modulating variables like stress levels or baseline neurobiology and neuro-psychopathology. The additive and potentially synergistic interaction between reward deficiency and anti-reward (127) were discussed above. Competition may be the another prominent interaction because incentive sensitization produces the opposite to reward deficiency, increases in motivational salience (26). Increases in motivation which lead to further hypofunctionality of the brain circuits mediating reward and motivation, clinically noticeable as a diminution of drives and capacity to experience pleasure (26), viz., RDS (2).

Interventions with the goal of restoring the balance between reward and anti-reward networks in patients with chronic pain may help to decrease their risk for suicide (129). Elman and associates suggest the Combined Reward Deficiency and Anti-Reward Model (CReAM) in which biopsychosocial variables can modulate brain reward, motivation, and stress functions can interact in a 'spiraling downward' fashion which exacerbates the intensity, chronicity, and comorbidities of chronic pain syndromes (127).

Certainly, the role of serotonin, orexin, and dopamine have been studied and elucidated regarding stress induction and influence on corticosterone activity (130). Most recently Zoratto *et al.* (131) have shown that in adult tryptophane-depleted and corticosterone augmented rats, offspring showed significantly increased anhedonia-related behaviors; reduced striatal and increased hypothalamic BDNF and reduced dopamine and serotonin in the prefrontal cortex and turnover in the hippocampus. Zoratto *et al.* (131) proposed that neonatal variations in functionality of the serotonergic system and HPA axis may contribute to induce anhedonia in adulthood.

It is well established that the nucleus accumbens shell (NAc S) is implicated in controlling stress responses through corticotrophin-releasing factor (CRF). As well as studies indicating that CRF in the NAc S increases appetitive motivation, there is indirect evidence indicating that NAc S CRF may also cause aversive responses and that these behaviors such as anhedonia may be mediated through local DA and acetylcholine (ACh) systems (132). Chen *et al.* found that NAc S CRF can induce some aversive behaviors; they include approach behavior, swim depression (a mouse model of depression), anhedonia, and anxiety. They propose that these behaviors through enhanced activation of ACh and DA in the NAc S, respectively, support a role for this brain area in mediating the effects of stress and anhedonia and involvement of multiple neurotransmitter deficits (132-135).

8. ANHEDONIA STATE OF THE ART

Over the last two years, some important papers have extended our knowledge about anhedonia. Signaling deficits in central, subcortical DA regions may underlie symptom severity, in particular, anhedonia in healthy subjects and schizophrenia. After genotyping for some dopamine-related gene polymorphisms (DRD4, DRD2/ANKK1, DAT1, and COMT) assessing DA receptor type 2 (D2R) binding, Eisenstein *et al.* (136) found that elevated subcortical dopaminergic signaling capacity is associated with less negative symptom severity. This finding supports the RDS concept. They also found that higher striatal D2R binding was associated with less physical and social anhedonia. This work suggests that subcortical DA function may contribute to negative symptom severity and self-reported anhedonia, independent of diagnostic status. From a clinical perspective, Sternat and Katzman (137) further support an umbrella concept such as RDS, by suggesting that patients diagnosed with major depressive disorder (MDD), SUD, and ADHD, all have low hedonic tone. The neuropathology of depressive-like behaviors is based on an anhedonic trait /state supported by the fact that the VTA DA neurons encode reward and motivation. Peroxisome proliferator-activated receptors type- α (PPAR α) acutely regulate VTA dopamine neuron firing via β 2 subunit-containing nicotinic acetylcholine receptors (β 2*nAChRs) through phosphorylation, and this effect is predictive of antidepressant-like effects. Scheggi *et al.* (138) proposed that regulating PPAR α with subsequent normalization of dopaminergic activity should reduce anhedonia.

It has been hypothesized by many that striatal dopamine receptor neurons D1 expression have associated with positive reinforcement and reward, whereas D2 neurons associate with negative reinforcement and aversion. However, most recently, Soares-Cunha *et al.*, (139) found that in control animals and in a model that presents Anhedonia and motivational deficits; activating NAc D2 neurons increases cue-induced motivational drive. Conversely, optogenetic inhibition of D2 neurons decreases motivation. Their results suggest that the classic view of D1-D2 functional antagonism does not hold true for all dimensions of reward-related behaviors and those D2 neurons may play a more prominent pro-motivation role than originally anticipated. Also, work of Ferenczi *et al.* (140) strongly suggests that by using optogenetic functional magnetic resonance imaging (fMRI) to visualize neural activity in rats, seen locally, striatal activity is driven by dopamine neuron stimulation. Whereas locally medial prefrontal cortex (mPFC) excitability increases, reduce striatal response and drives for behavioral dopaminergic stimulation. This chronic mPFC overactivity stably suppresses natural reward-motivated behaviors and

specific new brain-wide functional interactions induced which are predictive of the degree of anhedonia in individuals. Interestingly, Shen *et al.* (141) revealed that D1-D2 receptor heteromer induces development occurring in the NAc induces rapid anti-depressant (hedonia) and anxiolytic actions. They suggested that the development of D1-D2 receptor heteromer may have value as a novel therapeutic target. Enman *et al.* (142) found evidence showing that reduced D2 activity but not D1 activity caused anhedonia and therefore also reduced cocaine-induced reward behavior. Finally, Morie *et al.* (143) using high-density electrical mapping in cocaine abusers showed that anhedonia is independent of executive dysfunction. Executive dysfunction was found in their map to most strongly associated with duration (severity) of drug abuse.

Berridge and Kringelbach (144) accurately suggest that “pleasure is mediated by well-developed mesocorticolimbic circuitry and serves adaptive functions. In affective disorders, anhedonia (lack of pleasure) or dysphoria (negative affect) can result from breakdowns of that hedonic system.”

9. CONCLUSION

Neurobiological reward processing dysregulation is how, pleasure in previously rewarding stimuli, is lost. Anhedonia is actualized as a core symptom of MDD. The brain's mesolimbic dopamine reward circuit is integral to processing the rewarding salience of stimuli to guide actions (wanting), while, pleasure itself, (liking), may be generated within the limbic circuitry hedonic hot spots (144). The manifestation of anhedonia and associated symptoms of depression like appetite changes, feelings of sadness, and psychomotor effects, reflect altered brain reward circuitry as a common underlying disease process. Studies of cocaine self-administration, abstinence, and post-abstinence in laboratory animals and humans has emphasized the importance of dopamine, pleasure, and anhedonia (117). Mapping the neurogenetic antecedents of RDS behaviors may provide a method for risk assessment of an individual for developing anhedonia. However, especially following long-term drug abuse of, for example, psychostimulants, it is likely that anhedonia reflects drug induced epigenetic mesolimbic changes compounded by genetic antecedents. The response is low hedonic tone (137) suggesting that agonistic dopaminergic functioning may induce anti-anhedonia. Thus, treatment to attenuate anhedonia is to provide natural activation of dopaminergic receptors (D2/ D3) at the brain sites for craving and relapse and to increase dopamine sensitivity. Additional studies are necessary. In the meantime, diet, exercise, and other approaches to ‘normalize’ the dopamine system make sense.

10. ACKNOWLEDGEMENTS

This study was partly supported by NIH grant R01NS073884 awarded to RDB and VA merit review grant number 1 I01 CX001118-01A2 awarded to IE.

11. REFERENCES

1. M. T. Treadway and D. H. Zald: Reconsidering anhedonia in depression: lessons from translational neuroscience. *Neurosci Biobehav Rev*, 35(3), 537-55 (2011)
DOI: 10.1016/j.neubiorev.2010.06.006
PMid:20603146 PMCID:PMC3005986
2. S. Surguladze, P. Keedwell and M. Phillips: Neural systems underlying affective disorders. *Advances in Psychiatric Treatment*, 9(6), 446 (2003)
DOI: 10.1192/apt.9.6.446
3. K. Blum, M. Oscar-Berman, J. Giordano, B. Downs, T. Simpatico, D. Han and J. Femino: Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. *J Genet Syndr Gene Ther*, 3(4) (2012)
4. P. A. Keedwell and D. E. Linden: Integrative neuroimaging in mood disorders. *Curr Opin Psychiatry*, 26(1), 27-32 (2013)
DOI: 10.1097/YCO.0b013e32835a0b63
PMid:23108231
5. M. Lambert, B. G. Schimmelmann, A. Karow and D. Naber: Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. *Pharmacopsychiatry*, 36 Suppl 3, S181-90 (2003)
6. W. H. Liu, L. Z. Wang, Y. H. Zhu, M. H. Li and R. C. Chan: Clinical utility of the Snaith-Hamilton-Pleasure scale in the Chinese settings. *BMC Psychiatry*, 12, 184 (2012)
7. G. MS: Tobacco. In: *Drugs of abuse: a comprehensive series for clinicians*. Plenum Medical Book Company, New York & London (1995)
8. Miller NS and G. MS: Comorbid cigarette and addiction: epidemiology and treatment. In: *Smoking and Illicit Drug Use*. Ed G. MS. Haworth Medical Press, New York (1998)
9. I. R. Rockett, C. L. Lilly, H. Jia, G. L. Larkin, T. R. Miller, L. S. Nelson, K. B. Nolte, S. L. Putnam, G. S. Smith and E. D. Caine: Self-injury Mortality in the United States in the Early 21st Century: A Comparison With Proximally Ranked Diseases. *JAMA Psychiatry*, 73(10), 1072-1081 (2016)
DOI: 10.1001/jamapsychiatry.2016.1870
PMid:27556270 PMCID:PMC5482223
10. K. C. Berridge: The debate over dopamine's role in reward: the case for incentive salience. *Psychopharmacology (Berl)*, 191(3), 391-431 (2007)
DOI: 10.1007/s00213-006-0578-x
PMid:17072591
11. J. D. Salamone and M. Correa: The mysterious motivational functions of mesolimbic dopamine. *Neuron*, 76(3), 470-85 (2012)
DOI: 10.1016/j.neuron.2012.10.021
PMid:23141060 PMCID:PMC4450094
12. J. D. Salamone, M. Correa, A. Farrar and S. M. Mingote: Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. *Psychopharmacology (Berl)*, 191(3), 461-82 (2007)
DOI: 10.1007/s00213-006-0668-9
PMid:17225164
13. W. Schultz: Multiple dopamine functions at different time courses. *Annu Rev Neurosci*, 30, 259-88 (2007)
DOI: 10.1146/annurev.neuro.28.061604.135722
PMid:17600522
14. P. J. Edge and M. S. Gold: Drug withdrawal and hyperphagia: lessons from tobacco and other drugs. *Curr Pharm Des*, 17(12), 1173-9 (2011)
DOI: 10.2174/138161211795656738
PMid:21492091
15. M. S. Gold and M. J. Herkov: Tobacco smoking and nicotine dependence: biological basis for pharmacotherapy from nicotine to treatments that prevent relapse. *J Addict Dis*, 17(1), 7-21 (1998)
DOI: 10.1300/J069v17n01_02
PMid:9549599
16. N. M. Avena, A. N. Gearhardt, M. S. Gold, G. J. Wang and M. N. Potenza: Tossing the baby out with the bathwater after a brief rinse? The potential downside of dismissing food addiction based on limited data. *Nat Rev Neurosci*, 13(7), 514; author reply 514 (2012)

17. E. Stice, S. Yokum, K. Blum and C. Bohon: Weight gain is associated with reduced striatal response to palatable food. *J Neurosci*, 30(39), 13105-9 (2010)
DOI: 10.1523/JNEUROSCI.2105-10.2010
PMid:20881128 PMCID:PMC2967483
18. A. SH: Is Sugar as Addictive as Cocaine? In: *Food and Addiction*. Ed Brownell KD&G. MS. Oxford University Press, UK and New York (2012)
19. S. H. Ahmed: Imbalance between drug and non-drug reward availability: a major risk factor for addiction. *Eur J Pharmacol*, 526(1-3), 9-20 (2005)
20. R. J. Johnson, M. S. Gold, D. R. Johnson, T. Ishimoto, M. A. Lanaspá, N. R. Zahniser and N. M. Avena: Attention-deficit/hyperactivity disorder: is it time to reappraise the role of sugar consumption? *Postgrad Med*, 123(5), 39-49 (2011)
21. R. D. Badgaiyan, S. Sinha, M. Sajjad and D. S. Wack: Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder. *PLoS One*, 10(9), e0137326 (2015)
DOI: 10.1371/journal.pone.0137326
PMid:26422146 PMCID:PMC4589406
22. K. Blum, P. J. Sheridan, R. C. Wood, E. R. Braverman, T. J. Chen, J. G. Cull and D. E. Comings: The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. *J R Soc Med*, 89(7), 396-400 (1996)
23. M. Febo, K. Blum, R. D. Badgaiyan, D. Baron, P. K. Thanos, L. M. Colon-Perez, Z. Demetrovics and M. S. Gold: Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome. *Front Biosci (Landmark Ed)*, 22, 669-691 (2017)
DOI: 10.2741/4509
24. E. L. Gardner: Addiction and brain reward and anti-reward pathways. *Adv Psychosom Med*, 30, 22-60 (2011)
DOI: 10.1159/000324065
PMid:21508625 PMCID:PMC4549070
25. A. I. Green, S. V. Zimmet, R. D. Strous and J. J. Schildkraut: Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? *Harv Rev Psychiatry*, 6(6), 287-96 (1999)
26. T. E. Robinson and K. C. Berridge: The psychology and neurobiology of addiction: an incentive-sensitization view. *Addiction*, 95 Suppl 2, S91-117 (2000)
27. Gold MS and M. NS.: Cocaine (and crack): neurobiology. In: *Substance Abuse: A Comprehensive Textbook*. Ed Lowinson J, Ruiz P&M. R. Williams and Wilkins, New York (1997)
28. K. Blum, M. Febo, R. D. Badgaiyan, E. R. Braverman, K. Dushaj, M. Li, S. You and Z. Demetrovics: Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. *Curr Pharm Des* (2016)
29. X. Zhang, M. R. Lee, B. J. Salmeron, D. J. Stein, L. E. Hong, X. Geng, T. J. Ross, N. Li, C. Hodgkinson, P. H. Shen, Y. Yang, D. Goldman and E. A. Stein: Prefrontal white matter impairment in substance users depends upon the catechol-O-methyl transferase (COMT) val158met polymorphism. *Neuroimage*, 69, 62-9 (2013)
DOI: 10.1016/j.neuroimage.2012.11.056
PMid:23219927
30. K. Blum, A. L. Chen, J. Giordano, J. Borsten, T. J. Chen, M. Hauser, T. Simpatico, J. Femino, E. R. Braverman and D. Barh: The addictive brain: all roads lead to dopamine. *J Psychoactive Drugs*, 44(2), 134-43 (2012)
DOI: 10.1080/02791072.2012.685407
PMid:22880541
31. K. Blum, E. Seifter and J. Seifter: The pharmacology of d- and l-carnitine and d- and l-acetylcarnitine. Comparison with choline and acetylcholine. *J Pharmacol Exp Ther*, 178(2), 331-8 (1971)
32. G. Martinotti, S. Andreoli, D. Reina, M. Di Nicola, I. Ortolani, D. Tedeschi, F. Fanella, G. Pozzi, E. Iannoni, S. D'Iddio and L. J. Prof: Acetyl-L-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. *Prog Neuropsychopharmacol Biol Psychiatry*, 35(4), 953-8 (2011)
DOI: 10.1016/j.pnpbp.2011.01.013
PMid:21256179
33. R. A. Wise: Neuroleptics and operant behavior: The anhedonia hypothesis. *Behavioral and Brain Sciences*, 5(1), 39-53 (2010)
DOI: 10.1017/S0140525X00010372

34. R. A. Wise: Catecholamine theories of reward: a critical review. *Brain Res*, 152(2), 215-47 (1978)
DOI: 10.1016/0006-8993(78)90253-6
35. H. C. Fibiger: Drugs and reinforcement mechanisms: a critical review of the catecholamine theory. *Annu Rev Pharmacol Toxicol*, 18, 37-56 (1978)
DOI: 10.1146/annurev.pa.18.040178.000345
PMid:348064
36. C. A. Dackis and M. S. Gold: New concepts in cocaine addiction: the dopamine depletion hypothesis. *Neurosci Biobehav Rev*, 9(3), 469-77 (1985)
DOI: 10.1016/0149-7634(85)90022-3
37. L. Stein: Chemistry of reward and punishment. *Psychopharmacology: A review of progress*, 1967, 105-23 (1957)
38. L. Kayton and S. D. Koh: Hypohedonia in schizophrenia. *J Nerv Ment Dis*, 161(6), 412-20 (1975)
DOI: 10.1097/00005053-197512000-00005
PMid:1194910
39. H. L. Fields and E. B. Margolis: Understanding opioid reward. *Trends Neurosci*, 38(4), 217-25 (2015)
DOI: 10.1016/j.tins.2015.01.002
PMid:25637939 PMCID:PMC4385443
40. R. A. Wise: Dopamine and reward: the anhedonia hypothesis 30 years on. *Neurotox Res*, 14(2-3), 169-83 (2008)
41. K. Blum, J. D. Eubanks, J. E. Wallace and H. Hamilton: Enhancement of alcohol withdrawal convulsions in mice by haloperidol. *Clin Toxicol*, 9(3), 427-34 (1976)
DOI: 10.3109/15563657608988141
PMid:986285
42. G. Di Chiara: Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. *Behav Brain Res*, 137(1-2), 75-114 (2002)
43. K. Blum, M. Oscar-Berman, R. D. Badgaiyan, T. Palomo and M. S. Gold: Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. *Med Hypotheses*, 82(5), 606-14 (2014)
DOI: 10.1016/j.mehy.2014.02.019
PMid:24636783 PMCID:PMC4039414
44. T. Archer, M. Oscar-Berman, K. Blum and M. Gold: Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry. *J Genet Syndr Gene Ther*, 3(3), 1000115 (2012)
DOI: 10.4172/2157-7412.1000115
45. A. Bowirrat, T. J. Chen, M. Oscar-Berman, M. Madigan, A. L. Chen, J. A. Bailey, E. R. Braverman, M. Kerner, J. Giordano, S. Morse, B. W. Downs, R. L. Waite, F. Fornari, Z. Armaly and K. Blum: Neuropsychopharmacology and neurogenetic aspects of executive functioning: should reward gene polymorphisms constitute a diagnostic tool to identify individuals at risk for impaired judgment? *Mol Neurobiol*, 45(2), 298-313 (2012)
46. S. Robinson, S. M. Sandstrom, V. H. Denenberg and R. D. Palmiter: Distinguishing whether dopamine regulates liking, wanting, and/or learning about rewards. *Behav Neurosci*, 119(1), 5-15 (2005)
DOI: 10.1037/0735-7044.119.1.5
PMid:15727507
47. J. A. Heinsbroek, D. N. Neuhof, W. C. Griffin, 3rd, G. S. Siegel, A. C. Bobadilla, Y. M. Kupchik and P. W. Kalivas: Loss of Plasticity in the D2-Accumbens Pallidal Pathway Promotes Cocaine Seeking. *J Neurosci*, 37(4), 757-767 (2017)
DOI: 10.1523/JNEUROSCI.2659-16.2016
PMid:28123013 PMCID:PMC5296778
48. D. Healy: Neuroleptics and psychic indifference: a review. *J R Soc Med*, 82(10), 615-9 (1989)
49. R. H. Belmaker and D. Wald: Haloperidol in normals. *Br J Psychiatry*, 131, 222-3 (1977)
DOI: 10.1192/bjp.131.2.222b
PMid:263590
50. L. E. Hollister, D. T. Eikenberry and S. Raffel: Chlorpromazine in nonpsychotic patients with pulmonary tuberculosis. *Am Rev Respir Dis*, 81, 562-6 (1960)
51. K. Blum, Y. Liu, R. Shriner and M. S. Gold: Reward circuitry dopaminergic activation regulates food and drug craving behavior. *Curr Pharm Des*, 17(12), 1158-67 (2011)
DOI: 10.2174/138161211795656819
PMid:21492092
52. D. Tomasi and N. D. Volkow: Striatocortical pathway dysfunction in addiction and

- obesity: differences and similarities. *Crit Rev Biochem Mol Biol*, 48(1), 1-19 (2013)
DOI: 10.3109/10409238.2012.735642
PMid:23173916 PMCID:PMC3557663
53. Bijerot N: Addiction to pleasure: a biological and social-psychological theory of addiction. In: *Theories on Drug Abuse: Selected Contemporary Perspectives*. Ed Lettieri DJ, Sayersand M&P. HW. National Institute on Drug Abuse, Rockville, MD (1980)
 54. Axelrod J: Amphetamine: metabolism, physiological disposition, and its effects on catecholamine storage. In: *Amphetamines and Related Compounds*. Ed Costa E&G. S. Raven Press, New York (1970)
 55. Carlsson A: Amphetamine and brain catecholamines. In: *Amphetamines and Related Compounds*. Ed Costa E&Garattini S. Raven Press, New York (1970)
 56. R. J. van, S. J. van der and J. A. Hurkmans: Mechanism of action of cocaine and amphetamine in the brain. *Experientia*, 18, 229-31 (1962)
DOI: 10.1007/BF02148316
 57. A. A. Grace: The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. *Addiction*, 95 Suppl 2, S119-28 (2000)
 58. L. M. Gunne, E. Anggard and L. E. Jonsson: Clinical trials with amphetamine-blocking drugs. *Psychiatr Neurol Neurochir*, 75(3), 225-6 (1972)
 59. L. E. Jonsson, E. Anggard and L. M. Gunne: Blockade of intravenous amphetamine euphoria in man. *Clin Pharmacol Ther*, 12(6), 889-96 (1971)
DOI: 10.1002/cpt1971126889
PMid:4944167
 60. M. A. De Luca, M. Solinas, Z. Bimpisidis, S. R. Goldberg and G. Di Chiara: Cannabinoid facilitation of behavioral and biochemical hedonic taste responses. *Neuropharmacology*, 63(1), 161-8 (2012)
DOI: 10.1016/j.neuropharm.2011.10.018
PMid:22063718 PMCID:PMC3705914
 61. R. A. Bressan and J. A. Crippa: The role of dopamine in reward and pleasure behaviour-review of data from preclinical research. *Acta Psychiatr Scand Suppl*(427), 14-21 (2005)
 62. J. G. Pfaus, T. Scardochoio, M. Parada, C. Gerson, G. R. Quintana and G. A. Coria-Avila: Do rats have orgasms? *Socioaffect Neurosci Psychol*, 6, 31883 (2016)
 63. N. Alia-Klein, M. A. Parvaz, P. A. Woicik, A. B. Konova, T. Maloney, E. Shumay, R. Wang, F. Telang, A. Biegan, G. J. Wang, J. S. Fowler, D. Tomasi, N. D. Volkow and R. Z. Goldstein: Gene x disease interaction on orbitofrontal gray matter in cocaine addiction. *Arch Gen Psychiatry*, 68(3), 283-94 (2011)
DOI: 10.1001/archgenpsychiatry.2011.10
PMid:21383264 PMCID:PMC3127452
 64. A. B. Baransel Isir, S. Oguzkan, M. Nacak, S. Gorucu, H. E. Dulger and A. Arslan: The catechol-O-methyl transferase Val158Met polymorphism and susceptibility to cannabis dependence. *Am J Forensic Med Pathol*, 29(4), 320-2 (2008)
DOI: 10.1097/PAF.0b013e3181847e56
PMid:19259017
 65. G. Bart, M. J. Kreek, J. Ott, K. S. LaForge, D. Proudnikov, L. Pollak and M. Heilig: Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. *Neuropsychopharmacology*, 30(2), 417-22 (2005)
DOI: 10.1038/sj.npp.1300598
PMid:15525999
 66. J. Biederman, C. R. Petty, K. S. Ten Haagen, J. Small, A. E. Doyle, T. Spencer, E. Mick, M. C. Monuteaux, J. W. Smoller and S. V. Faraone: Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder. *Psychiatry Res*, 170(2-3), 199-203 (2009)
 67. K. Blum, E. P. Noble, P. J. Sheridan, A. Montgomery, T. Ritchie, P. Jagadeeswaran, H. Nogami, A. H. Briggs and J. B. Cohn: Allelic association of human dopamine D2 receptor gene in alcoholism. *JAMA*, 263(15), 2055-60 (1990)
DOI: 10.1001/jama.1990.03440150063027
DOI: 10.1001/jama.263.15.2055
PMid:1969501
 68. W. Byerley, M. Hoff, J. Holik, M. G. Caron and B. Ginos: VNTR polymorphism for the

- human dopamine transporter gene (DAT1). *Hum Mol Genet*, 2(3), 335 (1993)
DOI: 10.1093/hmg/2.3.335
PMid:8098980
69. V. Contini, F. Z. Marques, C. E. Garcia, M. H. Hutz and C. H. Bau: MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol dependence. *Am J Med Genet B Neuropsychiatr Genet*, 141b(3), 305-8 (2006)
70. E. H. Cook, Jr., M. A. Stein, M. D. Krasowski, N. J. Cox, D. M. Olkon, J. E. Kieffer and B. L. Leventhal: Association of attention-deficit disorder and the dopamine transporter gene. *Am J Hum Genet*, 56(4), 993-8 (1995)
71. A. Dahlgren, H. L. Wargelius, K. J. Berglund, C. Fahlke, K. Blennow, H. Zetterberg, L. Oreland, U. Berggren and J. Balldin: Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? A pilot study. *Alcohol Alcohol*, 46(5), 509-13 (2011)
DOI: 10.1093/alcalc/agr045
PMid:21613303
72. Z. Demetrovics, G. Varga, A. Szekely, A. Vereczkei, J. Csorba, H. Balazs, K. Hoffman, M. Sasvari-Szekely and C. Barta: Association between Novelty Seeking of opiate-dependent patients and the catechol-O-methyltransferase Val(158)Met polymorphism. *Compr Psychiatry*, 51(5), 510-5 (2010)
DOI: 10.1016/j.comppsy.2009.11.008
PMid:20728009
73. E. Duaux, P. Gorwood, N. Griffon, M. C. Bourdel, F. Sautel, P. Sokoloff, J. C. Schwartz, J. Ades, H. Loo and M. F. Poirier: Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. *Mol Psychiatry*, 3(4), 333-6 (1998)
DOI: 10.1038/sj.mp.4000409
PMid:9702742
74. S. V. Faraone, A. E. Doyle, E. Mick and J. Biederman: Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. *Am J Psychiatry*, 158(7), 1052-7 (2001)
DOI: 10.1176/appi.ajp.158.7.1052
PMid:11431226
75. J. Feusner, T. Ritchie, B. Lawford, R. M. Young, B. Kann and E. P. Noble: GABA(A) receptor beta 3 subunit gene and psychiatric morbidity in a post-traumatic stress disorder population. *Psychiatry Res*, 104(2), 109-17 (2001)
DOI: 10.1016/S0165-1781(01)00296-7
76. A. R. Galeeva, A. E. Gareeva, E. B. Iur'ev and E. K. Khusnutdinova: (VNTR polymorphisms of the serotonin transporter and dopamine transporter genes in male opiate addicts). *Mol Biol (Mosk)*, 36(4), 593-8 (2002)
DOI: 10.1023/A:1019883806620
77. C. Gokturk, S. Schultze, K. W. Nilsson, L. von Knorring, L. Oreland and J. Hallman: Serotonin transporter (5-HTTLPR) and monoamine oxidase (MAOA) promoter polymorphisms in women with severe alcoholism. *Arch Womens Ment Health*, 11(5-6), 347-55 (2008)
78. A. Grzywacz, J. Kucharska-Mazur and J. Samochowiec: (Association studies of dopamine D4 receptor gene exon 3 in patients with alcohol dependence). *Psychiatr Pol*, 42(3), 453-61 (2008)
79. F. S. Hall, I. Sora and G. R. Uhl: Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. *Psychopharmacology (Berl)*, 154(1), 43-9 (2001)
DOI: 10.1007/s002130000622
80. S. Y. Hill, E. K. Hoffman, N. Zezza, A. Thalamuthu, D. E. Weeks, A. G. Matthews and I. Mukhopadhyay: Dopaminergic mutations: within-family association and linkage in multiplex alcohol dependence families. *Am J Med Genet B Neuropsychiatr Genet*, 147b(4), 517-26 (2008)
81. E. Kosek, K. B. Jensen, T. B. Lonsdorf, M. Schalling and M. Ingvar: Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid Remifentanyl in humans. *Mol Pain*, 5, 37 (2009)
82. M. Kotler, H. Cohen, R. Segman, I. Gritsenko, L. Nemanov, B. Lerer, I. Kramer, M. Zer-Zion, I. Kletz and R. P. Ebstein: Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. *Mol Psychiatry*, 2(3), 251-4 (1997)
DOI: 10.1038/sj.mp.4000248
PMid:9152990

83. A. Kraschewski, J. Reese, I. Angheliescu, G. Winterer, L. G. Schmidt, J. Gallinat, U. Finckh, H. Rommelspacher and C. Wernicke: Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. *Pharmacogenet Genomics*, 19(7), 513-27 (2009)
DOI: 10.1097/FPC.0b013e32832d7fd3
PMid:19603545
84. J. H. Lai, Y. S. Zhu, Z. H. Huo, R. F. Sun, B. Yu, Y. P. Wang, Z. Q. Chai and S. B. Li: Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction. *Brain Res*, 1359, 227-32 (2010)
DOI: 10.1016/j.brainres.2010.08.064
PMid:20801104
85. S. S. Lee, B. B. Lahey, I. Waldman, C. A. Van Hulle, P. Rathouz, W. E. Pelham, J. Loney and E. H. Cook: Association of dopamine transporter genotype with disruptive behavior disorders in an eight-year longitudinal study of children and adolescents. *Am J Med Genet B Neuropsychiatr Genet*, 144b(3), 310-7 (2007)
86. S. Y. Lee, S. L. Chen, S. H. Chen, C. H. Chu, Y. H. Chang, S. H. Lin, S. Y. Huang, N. S. Tzeng, P. H. Kuo, I. H. Lee, T. L. Yeh, Y. K. Yang and R. B. Lu: Interaction of the DRD3 and BDNF gene variants in subtyped bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*, 39(2), 382-7 (2012)
DOI: 10.1016/j.pnpbp.2012.07.015
PMid:22877924
87. T. Li, Y. Hou, W. Cao, C. X. Yan, T. Chen and S. B. Li: Role of dopamine D3 receptors in basal nociception regulation and in morphine-induced tolerance and withdrawal. *Brain Res*, 1433, 80-4 (2012)
DOI: 10.1016/j.brainres.2011.11.045
PMid:22154407
88. F. Limosin, L. Romo, P. Batel, J. Ades, C. Boni and P. Gorwood: Association between dopamine receptor D3 gene Ball polymorphism and cognitive impulsiveness in alcohol-dependent men. *Eur Psychiatry*, 20(3), 304-6 (2005)
DOI: 10.1016/j.eurpsy.2005.02.004
PMid:15935433
89. L. Merenakk, J. Maestu, N. Nordquist, J. Parik, L. Oreland, H. M. Loit and J. Harro: Effects of the serotonin transporter (5-HTTLPR) and alpha2A-adrenoceptor (C-1291G) genotypes on substance use in children and adolescents: a longitudinal study. *Psychopharmacology (Berl)*, 215(1), 13-22 (2011)
DOI: 10.1007/s00213-010-2109-z
PMid:21140256
90. M. Mhatre and M. K. Ticku: Chronic ethanol treatment upregulates the GABA receptor beta subunit expression. *Brain Res Mol Brain Res*, 23(3), 246-52 (1994)
DOI: 10.1016/0169-328X(94)90231-3
91. C. Mulert, G. Juckel, I. Giegling, O. Pogarell, G. Leicht, S. Karch, P. Mavrogiorgou, H. J. Moller, U. Hegerl and D. Rujescu: A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. *Neuropsychopharmacology*, 31(6), 1335-44 (2006)
DOI: 10.1038/sj.npp.1300984
PMid:16395310
92. K. Namkoong, K. A. Cheon, J. W. Kim, J. Y. Jun and J. Y. Lee: Association study of dopamine D2, D4 receptor gene, GABAA receptor beta subunit gene, serotonin transporter gene polymorphism with children of alcoholics in Korea: a preliminary study. *Alcohol*, 42(2), 77-81 (2008)
DOI: 10.1016/j.alcohol.2008.01.004
PMid:18358985
93. G. Nedic, M. Nikolac, K. N. Sviglin, D. Muck-Seler, F. Borovecki and N. Pivac: Association study of a functional catechol-O-methyltransferase (COMT) Val108/158Met polymorphism and suicide attempts in patients with alcohol dependence. *Int J Neuropsychopharmacol*, 14(3), 377-88 (2011)
DOI: 10.1017/S1461145710001057
PMid:20860878
94. M. J. Neville, E. C. Johnstone and R. T. Walton: Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. *Hum Mutat*, 23(6), 540-5 (2004)
DOI: 10.1002/humu.20039
PMid:15146457
95. V. Nikulina, C. S. Widom and L. M. Brzustowicz: Child abuse and neglect, MAOA, and mental health outcomes: a prospective examination. *Biol Psychiatry*, 71(4), 350-7 (2012)
DOI: 10.1016/j.biopsych.2011.09.008
PMid:22030358 PMCID:PMC3295575

96. K. W. Nilsson, E. Comasco, C. Aslund, N. Nordquist, J. Leppert and L. Oreland: MAOA genotype, family relations and sexual abuse in relation to adolescent alcohol consumption. *Addict Biol*, 16(2), 347-55 (2011)
DOI: 10.1111/j.1369-1600.2010.00238.x
PMid:20731636
97. E. P. Noble: The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. *Alcohol*, 16(1), 33-45 (1998)
DOI: 10.1016/S0741-8329(97)00175-4
98. E. P. Noble, K. Blum, T. Ritchie, A. Montgomery and P. J. Sheridan: Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. *Arch Gen Psychiatry*, 48(7), 648-54 (1991)
DOI: 10.1001/archpsyc.1991.01810310066012
PMid:2069496
99. R. Ray, K. Ruparel, A. Newberg, E. P. Wileyto, J. W. Loughhead, C. Divgi, J. A. Blendy, J. Logan, J. K. Zubieta and C. Lerman: Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. *Proc Natl Acad Sci U S A*, 108(22), 9268-73 (2011)
DOI: 10.1073/pnas.1018699108
PMid:21576462 PMCID:PMC3107291
100. J. Reese, A. Kraschewski, I. Anghelescu, G. Winterer, L. G. Schmidt, J. Gallinat, F. Ruschendorf, H. Rommelspacher and C. Wernicke: Haplotypes of dopamine and serotonin transporter genes are associated with antisocial personality disorder in alcoholics. *Psychiatr Genet*, 20(4), 140-52 (2010)
DOI: 10.1097/YPG.0b013e32833a1ecb
PMid:20505557
101. A. F. Schellekens, B. Franke, B. Ellenbroek, A. Cools, C. A. de Jong, J. K. Buitelaar and R. J. Verkes: Reduced dopamine receptor sensitivity as an intermediate phenotype in alcohol dependence and the role of the COMT Val158Met and DRD2 Taq1A genotypes. *Arch Gen Psychiatry*, 69(4), 339-48 (2012)
DOI: 10.1001/archgenpsychiatry.2011.1335
PMid:22474103
102. R. Spangler, K. M. Wittkowski, N. L. Goddard, N. M. Avena, B. G. Hoebel and S. F. Leibowitz: Opiate-like effects of sugar on gene expression in reward areas of the rat brain. *Brain Res Mol Brain Res*, 124(2), 134-42 (2004)
DOI: 10.1016/j.molbrainres.2004.02.013
PMid:15135221
103. C. Y. Szeto, N. L. Tang, D. T. Lee and A. Stadlin: Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. *Neuroreport*, 12(6), 1103-6 (2001)
DOI: 10.1097/00001756-200105080-00011
PMid:11338173
104. L. K. Teh, A. F. Izuddin, H. F. M. Z. A. Zakaria and M. Z. Salleh: Tridimensional personalities and polymorphism of dopamine D2 receptor among heroin addicts. *Biol Res Nurs*, 14(2), 188-96 (2012)
DOI: 10.1177/1099800411405030
PMid:21613340
105. R. Tikkanen, L. Auvinen-Lintunen, F. Ducci, R. L. Sjoberg, D. Goldman, J. Tiihonen, I. Ojansuu and M. Virkkunen: Psychopathy, PCL-R, and MAOA genotype as predictors of violent reconvictions. *Psychiatry Res*, 185(3), 382-6 (2011)
DOI: 10.1016/j.psychres.2010.08.026
PMid:20850185 PMCID:PMC3506166
106. R. Treister, D. Pud, R. P. Ebstein, E. Laiba, E. Gershon, M. Haddad and E. Eisenberg: Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans. *Pain*, 147(1-3), 187-93 (2009)
107. C. S. van der Zwaluw, R. C. Engels, A. A. Vermulst, R. J. Rose, R. J. Verkes, J. Buitelaar, B. Franke and R. H. Scholte: A serotonin transporter polymorphism (5-HTTLPR) predicts the development of adolescent alcohol use. *Drug Alcohol Depend*, 112(1-2), 134-9 (2010)
108. H. H. Van Tol: Structural and functional characteristics of the dopamine D4 receptor. *Adv Pharmacol*, 42, 486-90 (1998)
DOI: 10.1016/S1054-3589(08)60794-2
109. V. Vengeliene, F. Leonardi-Essmann, S. Perreau-Lenz, P. Gebicke-Haerter, K. Drescher, G. Gross and R. Spanagel: The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse. *Faseb j*, 20(13), 2223-33 (2006)
DOI: 10.1096/fj.06-6110com
PMid:17077299

110. R. M. Young, B. R. Lawford, G. F. Feeney, T. Ritchie and E. P. Noble: Alcohol-related expectancies are associated with the D2 dopamine receptor and GABAA receptor beta3 subunit genes. *Psychiatry Res*, 127(3), 171-83 (2004)
DOI: 10.1016/j.psychres.2003.11.004
PMid:15296817
111. J. M. Bessa, M. Morais, F. Marques, L. Pinto, J. A. Palha, O. F. Almeida and N. Sousa: Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens. *Transl Psychiatry*, 3, e266 (2013)
112. S. A. Golden, D. J. Christoffel, M. Heshmati, G. E. Hodes, J. Magida, K. Davis, M. E. Cahill, C. Dias, E. Ribeiro, J. L. Ables, P. J. Kennedy, A. J. Robison, J. Gonzalez-Maeso, R. L. Neve, G. Turecki, S. Ghose, C. A. Tamminga and S. J. Russo: Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. *Nat Med*, 19(3), 337-44 (2013)
DOI: 10.1038/nm.3090
PMid:23416703 PMCid:PMC3594624
113. K. Blum, R. D. Badgaiyan, E. R. Braverman, K. Dushaj, M. Li, P. K. Thanos, Z. Demetrovics and M. Febo: Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term. *J Reward Defic Syndr Addict Sci*, 2(1), 14-21 (2016)
DOI: 10.17756/jrdsas.2016-023
PMid:28317038 PMCid:PMC5351297
114. D. G. Dillon, R. Bogdan, J. Fagerness, A. J. Holmes, R. H. Perlis and D. A. Pizzagalli: Variation in TREK1 gene linked to depression-resistant phenotype is associated with potentiated neural responses to rewards in humans. *Hum Brain Mapp*, 31(2), 210-21 (2010)
115. A. J. Law, Q. Pei, M. Walker, H. Gordon-Andrews, C. S. Weickert, J. Feldon, C. R. Pryce and P. J. Harrison: Early parental deprivation in the marmoset monkey produces long-term changes in hippocampal expression of genes involved in synaptic plasticity and implicated in mood disorder. *Neuropsychopharmacology*, 34(6), 1381-94 (2009)
DOI: 10.1038/npp.2008.106
PMid:18615010 PMCid:PMC2669475
116. M. S. Todtenkopf, A. Parsegian, A. Naydenov, R. L. Neve, C. Konradi and W. A. Carlezon, Jr.: Brain reward regulated by AMPA receptor subunits in nucleus accumbens shell. *J Neurosci*, 26(45), 11665-9 (2006)
DOI: 10.1523/JNEUROSCI.3070-06.2006
PMid:17093088 PMCid:PMC4205583
117. J. C. Felger, J. Mun, H. L. Kimmel, J. A. Nye, D. F. Drake, C. R. Hernandez, A. A. Freeman, D. B. Rye, M. M. Goodman, L. L. Howell and A. H. Miller: Chronic interferon-alpha decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. *Neuropsychopharmacology*, 38(11), 2179-87 (2013)
DOI: 10.1038/npp.2013.115
PMid:23657438 PMCid:PMC3773667
118. G. MS Dopamine depletion hypothesis for acute cocaine abstinence clinical observations, prolactin elevations, and persistent anhedonia/dysphoria *Neuro Endocrinol Lett*, 15(271) (1993)
119. R. M. Carelli and E. A. West: When a good taste turns bad: Neural mechanisms underlying the emergence of negative affect and associated natural reward devaluation by cocaine. *Neuropharmacology*, 76 Pt B, 360-9 (2014)
120. K. Blum, M. Gold, Z. Demetrovics, T. Archer, P. K. Thanos, D. Baron and R. D. Badgaiyan: Substance use disorder a bi-directional subset of reward deficiency syndrome. *Front Biosci (Landmark Ed)*, 22, 1534-1548 (2017)
DOI: 10.2741/4557
121. K. M. Tye, J. J. Mirzabekov, M. R. Warden, E. A. Ferenczi, H. C. Tsai, J. Finkelstein, S. Y. Kim, A. Adhikari, K. R. Thompson, A. S. Andalman, L. A. Gunaydin, I. B. Witten and K. Deisseroth: Dopamine neurons modulate neural encoding and expression of depression-related behaviour. *Nature*, 493(7433), 537-541 (2013)
DOI: 10.1038/nature11740
PMid:23235822 PMCid:PMC4160519
122. S. Sharma, M. F. Fernandes and S. Fulton: Adaptations in brain reward circuitry underlie palatable food cravings and anxiety induced by high-fat diet withdrawal. *Int J Obes (Lond)*, 37(9), 1183-91 (2013)
DOI: 10.1038/ijo.2012.197
PMid:23229740

123. B. K. Lim, K. W. Huang, B. A. Grueter, P. E. Rothwell and R. C. Malenka: Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens. *Nature*, 487(7406), 183-9 (2012)
DOI: 10.1038/nature11160
PMid:22785313 PMCID:PMC3397405
124. E. J. Modestino, K. Blum, M. Oscar-Berman, M. S. Gold, D. D. Duane, S. G. S. Sultan and S. H. Auerbach: Reward Deficiency Syndrome: Attentional/Arousal Subtypes, Limitations of Current Diagnostic Nosology, and Future Research. *J Reward Defic Syndr*, 1(1), 6-9 (2015)
DOI: 10.17756/jrds.2015-002
125. E. Venzala, A. L. Garcia-Garcia, N. Elizalde and R. M. Tordera: Social vs. environmental stress models of depression from a behavioural and neurochemical approach. *Eur Neuropsychopharmacol*, 23(7), 697-708 (2013)
DOI: 10.1016/j.euroneuro.2012.05.010
PMid:22743048
126. K. Blum, E. Gardner, M. Oscar-Berman and M. Gold: "Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. *Curr Pharm Des*, 18(1), 113-8 (2012)
DOI: 10.2174/138161212798919110
PMid:22236117 PMCID:PMC3651846
127. D. Borsook, C. Linnman, V. Faria, A. M. Strassman, L. Becerra and I. Elman: Reward deficiency and anti-reward in pain chronification. *Neurosci Biobehav Rev*, 68, 282-297 (2016)
DOI: 10.1016/j.neubiorev.2016.05.033
PMid:27246519
128. N. D. Volkow and J. M. Swanson: Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. *Am J Psychiatry*, 160(11), 1909-18 (2003)
DOI: 10.1176/appi.ajp.160.11.1909
PMid:14594733
129. I. Elman, D. Borsook and N. D. Volkow: Pain and suicidality: insights from reward and addiction neuroscience. *Prog Neurobiol*, 109, 1-27 (2013)
DOI: 10.1016/j.pneurobio.2013.06.003
PMid:23827972 PMCID:PMC4827340
130. C. Nocjar, J. Zhang, P. Feng and J. Panksepp: The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. *Neuroscience*, 218, 138-53 (2012)
DOI: 10.1016/j.neuroscience.2012.05.033
PMid:22626650
131. F. Zoratto, M. Fiore, S. F. Ali, G. Laviola and S. Macri: Neonatal tryptophan depletion and corticosterone supplementation modify emotional responses in adult male mice. *Psychoneuroendocrinology*, 38(1), 24-39 (2013)
DOI: 10.1016/j.psyneuen.2012.04.015
PMid:22613034
132. Y. W. Chen, P. V. Rada, B. P. Butzler, S. F. Leibowitz and B. G. Hoebel: Corticotropin-releasing factor in the nucleus accumbens shell induces swim depression, anxiety, and anhedonia along with changes in local dopamine/acetylcholine balance. *Neuroscience*, 206, 155-66 (2012)
DOI: 10.1016/j.neuroscience.2011.12.009
PMid:22245501
133. M. S. Gold and N. M. Avena: Animal models lead the way to further understanding food addiction as well as providing evidence that drugs used successfully in addictions can be successful in treating overeating. *Biol Psychiatry*, 74(7), e11 (2013)
DOI: 10.1016/j.biopsych.2013.04.022
PMid:23726509 PMCID:PMC4038094
134. Y. Lin, Y. Sarfraz, A. Jensen, A. J. Dunn and E. A. Stone: Participation of brainstem monoaminergic nuclei in behavioral depression. *Pharmacol Biochem Behav*, 100(2), 330-9 (2011)
DOI: 10.1016/j.pbb.2011.08.021
PMid:21893082 PMCID:PMC3199359
135. E. Vrieze, J. Ceccarini, D. A. Pizzagalli, G. Bormans, M. Vandenbulcke, K. Demyttenaere, K. Van Laere and S. Claes: Measuring extrastriatal dopamine release during a reward learning task. *Hum Brain Mapp*, 34(3), 575-86 (2013)
136. S. A. Eisenstein, R. Bogdan, L. Chen, S. M. Moerlein, K. J. Black, J. S. Perlmutter, T. Hershey and D. M. Barch: Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia. *J Psychiatr Res*, 86, 9-17

- (2017)
DOI: 10.1016/j.jpsychires.2016.11.007
PMid:27886638
137. T. Sternat and M. A. Katzman: Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. *Neuropsychiatr Dis Treat*, 12, 2149-64 (2016)
DOI: 10.2147/NDT.S111818
PMid:27601909 PMCID:PMC5003599
138. S. Scheggi, M. Melis, M. De Felice, S. Aroni, A. L. Muntoni, T. Pelliccia, C. Gambarana, M. G. De Montis and M. Pistis: PPARalpha modulation of mesolimbic dopamine transmission rescues depression-related behaviors. *Neuropharmacology*, 110(Pt A), 251-259 (2016)
139. C. Soares-Cunha, B. Coimbra, A. David-Pereira, S. Borges, L. Pinto, P. Costa, N. Sousa and A. J. Rodrigues: Activation of D2 dopamine receptor-expressing neurons in the nucleus accumbens increases motivation. *Nat Commun*, 7, 11829 (2016)
140. E. A. Ferenczi, K. A. Zalocusky, C. Liston, L. Grosenick, M. R. Warden, D. Amatya, K. Katovich, H. Mehta, B. Patenaude, C. Ramakrishnan, P. Kalanithi, A. Etkin, B. Knutson, G. H. Glover and K. Deisseroth: Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior. *Science*, 351(6268), aac9698 (2016)
141. M. Y. Shen, M. L. Perreault, F. R. Bambico, J. Jones-Tabah, M. Cheung, T. Fan, J. N. Nobrega and S. R. George: Rapid antidepressant and anxiolytic actions following dopamine D1-D2 receptor heteromer inactivation. *Eur Neuropsychopharmacol*, 25(12), 2437-48 (2015)
DOI: 10.1016/j.euroneuro.2015.09.004
PMid:26431907
142. N. M. Enman, K. Arthur, S. J. Ward, S. A. Perrine and E. M. Unterwald: Anhedonia, Reduced Cocaine Reward, and Dopamine Dysfunction in a Rat Model of Posttraumatic Stress Disorder. *Biol Psychiatry*, 78(12), 871-9 (2015)
DOI: 10.1016/j.biopsych.2015.04.024
PMid:26115790 PMCID:PMC4644715
143. K. P. Morie, P. De Sanctis, H. Garavan and J. J. Foxe: Executive dysfunction and reward dysregulation: a high-density electrical mapping study in cocaine abusers. *Neuropharmacology*, 85, 397-407 (2014)
DOI: 10.1016/j.neuropharm.2014.05.016
PMid:24911989 PMCID:PMC4385568
144. K. C. Berridge and M. L. Kringelbach: Pleasure systems in the brain. *Neuron*, 86(3), 646-64 (2015)
DOI: 10.1016/j.neuron.2015.02.018
PMid:25950633 PMCID:PMC4425246

Abbreviations: ACh: acetylcholine, ANKK1: ankyrin repeat and kinase domain containing 1 is a gene which controls the synthesis of dopamine in the brain, ANOVA: analysis of variance, ASAM: American Society of Addiction Medicine, COMT: catechol-O-methyltransferase (an enzyme), CRF: corticotropin-releasing factor, CSDS: chronic social defeat stress, DA: dopamine, DAT1: dopamine transporter polymorphism associated with ADHD, D2/D3: dopamine receptors, DRD2: dopamine receptor D2, GABA: γ -amino-butyric acid, IFN- α : interferon-alpha is a pleiotropic cytokine; part of the immune response signaling pathway, ICSS: intracranial self-stimulation, mRNA: messenger RNA, molecules that convey genetic information from DNA to ribosomes, NAc: nucleus accumbens, PFC: prefrontal cortex, RAS: family of related proteins belonging to GTPase class and is involved in cellular signal transduction., RDS: reward deficiency syndrome, SHAPS: Snaith-Hamilton-Pleasure-Scale, SNP: single-nucleotide polymorphism - most common type of genetic variation, Taq1A: polymorphism that can influence DRD2 receptor expression, TREK: Outward rectifying potassium channel

Key Words: Anhedonia, Hedonia, Dopamine, Reward Deficiency Syndrome, Neurogenetics, Neurobiology, Review

Send correspondence to: Kenneth Blum, Department of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA, Tel 352-294-4911, Fax 352-392-9887, E-mail: drd2gene@gmail.com